Navigation Links
Naviscan Positron Emission Mammography Technology Highlighted at the Society of Nuclear Medicine Annual Meeting
Date:6/18/2010

SAN DIEGO, June 18 /PRNewswire/ -- Naviscan's Positron Emission Mammography (PEM) technology was the focus of several presentations and discussions at the Society of Nuclear Medicine Annual Meeting in Salt Lake City.  The focus represents a growing interest and validation of how PEM can play an important role in the fight against breast cancer.  

PEM scanners are high-resolution breast PET systems that can show the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment. Other imaging systems, such as mammography and ultrasound, show only the location, not the metabolic phase. PEM scanners, which are about the size of an ultrasound system, are manufactured by Naviscan, Inc. and have been commercially available since 2007.

A presentation with considerable attention was of the release of the findings from the NIH-sponsored clinical study comparing PEM with breast MRI. This multi-site study (NIH Grant 5R44CA103102) of hundreds of women with newly diagnosed breast cancer shows that PEM may reduce unnecessary breast biopsies. The study found that PEM was significantly more precise at identifying benign and cancerous lesions, in what scientists call "Positive Predictive Value" or "PPV," therefore reducing the number of unnecessary biopsies.

Other presentations on PEM were led by leading researchers from M.D. Anderson Cancer Center, Johns Hopkins, Swedish Cancer Institute, University of Washington and Boston University.  These presentations covered not only the clinical advantages of PEM today, but also exciting new areas of focus.  

The triple negative cancer study results were particularly welcomed news.  The study enrolled 281 patients with newly diagnosed breast cancer and the results suggested that PEM may be able to properly characterize triple negative tumors.  Triple negative breast cancers make up between 13-38% of all breast cancers and are the most difficult to treat because they are so aggressive.

About Naviscan, Inc.

Naviscan, Inc., founded in 1995, develops and markets compact, high-resolution PET scanners for organ-specific molecular imaging and PET-guided radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance.  For more information, call 1.858.587.3641 or visit www.naviscan.com.


'/>"/>
SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment
2. Baylor Adds Naviscan PEM Technology to Womens Imaging Center
3. Johns Hopkins Medicine Acquires Naviscan PEM Technology for Novel Radiotracer Research
4. FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
5. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
6. FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
7. New Positron Emission Tomography (PET) Biomarker NVB-64 Visualizes Malignant Breast Tumors
8. Alliance Imaging Offers Mobile Positron Emission Mammography (PEM) Imaging to its Florida Customers
9. Researchers at MD Anderson Show That Positron Emission Mammography (PEM) Helps Evaluate Early Response to Neoadjuvant Chemotherapy
10. Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission
11. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed its ... health care service center company based in ... relationship management programs for leading pharmaceutical manufacturers and health ... WRB will join Envoy Health Management, LLC , ... biotech firms, and other service companies. Together, WRB and ...
(Date:5/4/2017)... May 4, 2017  A recent study published ... Ultraviolet-C light as a means of disinfection ... to reduce bioburden on anesthesia workstations. In the ... high-touch, complex medical equipment surfaces contaminated with three ... "This study further validates the body of ...
(Date:5/4/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... today announced that the Company,s first quarter 2017 financial ... May 11, 2017, and that the Company will host ... PT that afternoon. Management will provide an overview of ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... Therachat , a smart ... in an infographic on the current state of anxiety in support of National Mental ... was conducted in April 2017 and benchmarked general anxiety levels as well as identified ...
(Date:5/22/2017)... NC (PRWEB) , ... May 22, 2017 , ... ... Matthews Periodontics, is now welcoming new patients with periodontal plastic surgery treatments, including ... from a general dentist. Dr. Green provides these esthetic and functional procedures to ...
(Date:5/22/2017)... ... May 22, 2017 , ... Galena, Alaska, has a population of less ... headlines when it was targeted to build a nuclear plant by the TOSHIBA Corporation. ... manager Marvin L. Yoder describes the journey to get power to his small town, ...
(Date:5/21/2017)... (PRWEB) , ... May 19, 2017 , ... Chris Cornell, 52, was found dead on ... why one of the most respected lead singers in the rock industry would take his ... of mental illness. FindaTopDoc investigates how mental illness played a role in the death of ...
(Date:5/21/2017)... PARK, FL (PRWEB) , ... May 20, 2017 , ... ... sell it, find it, review it, and share its attributes like never before. More ... dispensary directory to connect cannabis enthusiasts to stores, strains, products – and for the ...
Breaking Medicine News(10 mins):